131 related articles for article (PubMed ID: 12594171)
1. Overexpression of interleukin-12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity.
Miller G; Lahrs S; Dematteo RP
FASEB J; 2003 Apr; 17(6):728-30. PubMed ID: 12594171
[TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
3. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
[TBL] [Abstract][Full Text] [Related]
4. Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function.
Osada T; Nagawa H; Kitayama J; Tsuno NH; Ishihara S; Takamizawa M; Shibata Y
Cell Immunol; 2001 Oct; 213(1):14-23. PubMed ID: 11747352
[TBL] [Abstract][Full Text] [Related]
5. IL-12p40-overexpressing immature dendritic cells induce T cell hyporesponsiveness in vitro but accelerate allograft rejection in vivo: role of NK cell activation and interferon-gamma production.
Sun W; He X; Guo Z; Wang Q; Li X; Rayner J; Zhang L; Wang J; Cao X
Immunol Lett; 2004 Jul; 94(3):191-9. PubMed ID: 15275966
[TBL] [Abstract][Full Text] [Related]
6. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
7. NK cells promote type 1 T cell immunity through modulating the function of dendritic cells during intracellular bacterial infection.
Jiao L; Gao X; Joyee AG; Zhao L; Qiu H; Yang M; Fan Y; Wang S; Yang X
J Immunol; 2011 Jul; 187(1):401-11. PubMed ID: 21642541
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation.
Jin GH; Hirano T; Murakami M
Int Immunol; 2008 Jun; 20(6):783-9. PubMed ID: 18448458
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
10. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
[TBL] [Abstract][Full Text] [Related]
11. Combined mobilization and stimulation of tumor-infiltrating dendritic cells and natural killer cells with Flt3 ligand and IL-18 in vivo induces systemic antitumor immunity.
Saito T; Takayama T; Osaki T; Nagai S; Suzuki T; Sato M; Kuwano H; Tahara H
Cancer Sci; 2008 Oct; 99(10):2028-36. PubMed ID: 19016763
[TBL] [Abstract][Full Text] [Related]
12. Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.
Moriya K; Wakabayashi A; Shimizu M; Tamura H; Dan K; Takahashi H
Cancer Immunol Immunother; 2010 Jul; 59(7):1083-95. PubMed ID: 20221597
[TBL] [Abstract][Full Text] [Related]
13. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
14. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
[TBL] [Abstract][Full Text] [Related]
15. IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells.
Gruenbacher G; Gander H; Nussbaumer O; Nussbaumer W; Rahm A; Thurnher M
Cancer Res; 2010 Dec; 70(23):9611-20. PubMed ID: 20947520
[TBL] [Abstract][Full Text] [Related]
16. Generation of antitumor response by IL-2-transduced JAWS II dendritic cells.
Rossowska J; Pajtasz-Piasecka E; Ryśnik O; Wojas J; Krawczenko A; Szyda A; Duś D
Immunobiology; 2011 Oct; 216(10):1074-84. PubMed ID: 21676487
[TBL] [Abstract][Full Text] [Related]
17. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
18. Decidual natural killer cell tuning by autologous dendritic cells.
Laskarin G; Redzović A; Rubesa Z; Mantovani A; Allavena P; Haller H; Vlastelić I; Rukavina D
Am J Reprod Immunol; 2008 May; 59(5):433-45. PubMed ID: 18405314
[TBL] [Abstract][Full Text] [Related]
19. Bovine NK cells acquire cytotoxic activity and produce IFN-gamma after stimulation by Mycobacterium bovis BCG- or Babesia bovis-exposed splenic dendritic cells.
Bastos RG; Johnson WC; Mwangi W; Brown WC; Goff WL
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):302-12. PubMed ID: 18514329
[TBL] [Abstract][Full Text] [Related]
20. Prolonged antitumor NK cell reactivity elicited by CXCL10-expressing dendritic cells licensed by CD40L+ CD4+ memory T cells.
Shimizu K; Asakura M; Fujii S
J Immunol; 2011 May; 186(10):5927-37. PubMed ID: 21460206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
